PATHOLOGIC STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for PATHOLOGIC STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new PATHOLOGIC STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for PATHOLOGIC STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy targets Hard-to-Treat stomach cancer
Disease control OngoingThis early-phase trial is testing whether adding the immunotherapy drug pembrolizumab to standard chemoradiotherapy can help control gastroesophageal cancer that cannot be removed by surgery. The study includes 16 participants and primarily looks at safety and whether the cancer …
Matched conditions: PATHOLOGIC STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 22, 2026 11:59 UTC
-
Experimental virus joins Chemo-Radiation to fight esophageal cancer
Disease control OngoingThis early-phase trial tests whether adding a cancer-killing virus (OBP-301) to standard chemotherapy and radiation is safe for people with advanced esophageal or gastroesophageal cancer who cannot have surgery. The study includes 16 participants and focuses on side effects. The …
Matched conditions: PATHOLOGIC STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 22, 2026 11:56 UTC
-
New combo therapy before surgery shows promise for esophageal cancer
Disease control OngoingThis study is testing whether adding two immunotherapy drugs (atezolizumab and tiragolumab) to standard chemotherapy before surgery can help control esophageal or gastroesophageal cancer. About 43 adults with stage II or III cancer will receive the drug combination, then undergo …
Matched conditions: PATHOLOGIC STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 18, 2026 11:52 UTC
-
Experimental combo targets Hard-to-Treat esophageal cancer
Disease control OngoingThis early-stage trial tested a drug called adavosertib together with radiation therapy for people with advanced esophageal or stomach cancer that cannot be surgically removed. The goal was to find the safest dose and see how well the combination works. Only 4 people took part, s…
Matched conditions: PATHOLOGIC STAGE III GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 09, 2026 12:06 UTC